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Background. Interleukin (IL)-7 promotes the generation, expansion, and survival of memory T cells. Previous mouse and 
human studies showed that IL-7 can support immune cell reconstitution in lymphopenic conditions, expand tumor-reactive T cells 
for adoptive immunotherapy, and enhance effector cytokine expression by autoreactive T cells. Whether pathogen-reactive T cells 
also benefit from IL-7 exposure remains unknown.
Methods. In this study, we investigated this issue in cultures of peripheral blood mononuclear cells (PBMCs) derived from 
patients infected with various endemic pathogens. After short-term exposure to IL-7, we measured PBMC responses to antigens 
derived from pathogens, such as Mycobacterium tuberculosis, Candida albicans, and cytomegalovirus, and to the superantigen 
Staphylococcus aureus enterotoxin B.
Results. We found that IL-7 favored the expansion and, in some instances, the uncovering of pathogen-reactive CD4 T cells, by 
promoting pathogen-specific interferon-γ, IL-2, and tumor necrosis factor recall responses.
Conclusions. Our findings indicate that IL-7 unveils and supports reactivation of pathogen-specific T cells with possible diagnos-
tic, prognostic, and therapeutic significance of clinical value, especially in conditions of pathogen persistence and chronic infection.
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Interleukin (IL)-7 [1] is a pleiotropic cytokine [2] regulating 
lymphopoiesis and T-cell homeostasis [3, 4]. It binds to a het-
erodimeric receptor formed by an α-chain (CD127 [3]), which 
is private to the IL-7 receptor (IL-7R) and the common-γ-chain 
cytokine-receptor (CD132 [5, 6]). In humans, mutations neg-
atively affecting the levels of CD127 have been correlated with 
severe immunodeficiency [7]. Conversely, increased serum lev-
els of IL-7 and/or dysregulated activation of CD127 are reported 
in patients with autoimmune conditions, including multiple 
sclerosis [8, 9], rheumatoid arthritis [10], type-I diabetes [11], 
inflammatory bowel disease [12], and psoriasis [13].
Upon antigen (Ag) encounter, IL-7 sustains the generation 
of memory T lymphocytes in vitro [14] and in vivo [14–16] 
and favors the transition of effector to central memory cells 
[17, 18] while driving their proliferation [19]. Via the JAK3/
STAT5 pathway and the upregulation of antiapoptotic factors 
(eg, Bcl-2) [14, 20], IL-7 promotes the long-term survival of 
naive and memory-phenotype cells. Recombinant IL-7 elicits a 
marked increase of central memory (TCM) and effector memory 
T cells (TEM) when administered to aged nonhuman primates 
[21] and lymphopenic patients and macaques infected with 
human immunodeficiency virus (HIV) or simian immunode-
ficiency virus, respectively [22–24]. Similar effects are reported 
in patients undergoing stem cell transplantation [25, 26], 
where IL-7 levels correlate with the generation of stem-cell 
memory T cells [26]. In cancer patients, IL-7 preferentially 
increases naive but not regulatory T-cell numbers [27], main-
taining T-cell receptor (TCR) repertoire diversity [28]. Hence, 
the immunotherapeutic use of IL-7 is increasingly proposed 
to favor immune-cell reconstitution and function after lym-
pho-depleting chemotherapy or in the elderly. In the setting of 
adoptive T-cell therapy (ACT), IL-7 has been used in primary 
cultures to engineer and expand tumor-reactive T cells [29, 30]. 
We previously found that IL-7 selectively expands tumor-reac-
tive CD4 T cells capable of promoting tumor protection in ACT 
[29]. Whether similar results could be extendible to patho-
gen-specific T cells remains unknown. Therefore, we sought to 
investigate the expansion of pathogen-reactive CD4 T cells in 
individuals affected by recurrent or persistent/chronic bacterial 
(Mycobacterium tuberculosis [MTB] and Staphylococcus aur-
eus), fungal (Candida albicans [Ca]), or viral (cytomegalovirus 
[CMV]) infections. We report that, in all cases, IL-7 enriched 
pathogen-specific CD4 T cells, enabling their detection and 
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sensitizing them to Ag-specific recall responses. Furthermore, 
IL-7 rescued chronically activated pathogen-specific effectors 
enhancing their Ag-recall responses. We believe that these data 
open new avenues for diagnostic, prognostic, and therapeutic 
applications.
MATERIALS AND METHODS
Classification of Tuberculosis Patients
Human immunodeficiency virus-seronegative patients with 
active tuberculosis ([TB] clinic and culture confirmed) were 
recruited at the Clinic of Infectious Diseases, San Raffaele 
Hospital (Milan, Italy). They underwent tuberculin skin test-
ing (TST) administered by the Mantoux method with 0.1 mL 
(5 tuberculin units) of Biocinetest-PPD tuberculin (Chiron 
Italia, Milan, Italy). The size of induration was evaluated after 
48–72 hours (an induration ≥10  mm was classified as posi-
tive). Peripheral blood was drawn before starting any therapy 
and following written informed consent. Healthy controls were 
selected among HIV-seronegative individuals with no history 
of TB exposure, no infection, and with negative reaction to the 
TST. Healthy controls were tested for the presence of Ca-Ag 
responses.
Ethics Statement
Written informed consent or consultee approval to enroll was 
secured for all study participants (patients and healthy donors). 
This study was approved by the Ethical Committee of the San 
Raffaele Scientific Institute, the UK National Research Ethics 
Service (reference: 13/LO/1270), and the Brighton and Sussex 
Medical School  (BSMS) Research Governance and Ethics 
Committee (reference: 13/182/LLE) and carried out in accord-
ance with the approved guidelines. All data were anonymized.
Cytomegalovirus Serology
Healthy donors were screened for the presence of CMV-specific 
antibody in serum. Cytomegalovirus immunoglobulin (Ig)G 
serology (Architect CMV IgG; Abbot, Maidenhead, UK) was 
performed at the Brighton and Sussex University Hospital Trust 
virology laboratory. Cytomegalovirus-seropositive and -seroneg-
ative individuals are referred to as CMV+ and CMV−, respectively.
Human Samples and T-Cell Cultures
Patients and healthy donors used for MTB- and Candida-
specific responses were part of a previously published 
cohort [31]. Donors (male/female, 10:9) used for CMV and 
Staphylococcus aureus enterotoxin B (SEB)-specific responses 
were 68  ±  17  years old. Peripheral blood mononuclear cells 
(PBMCs) were isolated by blood centrifugation over Ficoll-
Hypaque (Sigma/Merck, Darmstadt, Germany) density gradi-
ent. Cultures were derived either from freshly isolated (CMV/
SEB responses) or cryopreserved (90% fetal calf serum [FCS] and 
10% dimethyl sulfoxide; MTB/Ca-Ag responses) PBMCs. Equal 
numbers of viable (0.1% Trypan blue-negative) cells were resus-
pended in complete media (Roswell Park Memorial Institute 
medium containing penicillin, streptomycin, glutamine, and 
10% FCS [all from Thermo Fisher Scientific] or autologous 
serum) with or without human recombinant IL-7 (50 ng/mL, 
unless specified otherwise in individual figures; R&D Systems/
Biotechne, Minneapolis, MN) for 7 days. Where indicated, cells 
were stained with the fluorescent dye 5-(and-6)-carboxyflu-
orescein diacetate succinimidyl ester ([CFSE] Thermo Fisher 
Scientific; 1 µM), in accordance with the manufacturer’s instruc-
tions, using autologous serum or FCS to quench the labeling. 
Where indicated, cells were first cultured in complete medium 
with or without bacterial SEB (1 μg/mL, Sigma/Merck). After 
5 days, cells were harvested, washed and counted. Equal num-
ber of viable cells were finally seeded in culture with or with-
out IL-7, for additional 7 days (day 12). Cyclosporine A ([CSA] 
0.5  µg/mL; Calbiochem/Merck) or anti-lymphocyte func-
tion-associated antigen (LFA)-1 blocking antibody (5  µg/mL; 
a gift from Professor Ruggero Pardi, University Vita-Salute San 
Raffaele, Milan) were added to the cultures.
Mycobaterium tuberculosis Peptides and Candida albicans  
Antigen-Specific Enzyme-Linked Immunospot Assay
The enzyme-linked immunospot (ELISPOT) assay for interferon 
(IFN)γ detection was performed as described previously [31]. 
In brief, equal numbers of viable cells (5 × 104 cells/well) were 
seeded in duplicate in 96-well plates (MAIPS4510; Millipore/
Merck), precoated with anti-IFNγ capture monoclonal antibody 
([mAb] B-B1; Diaclone, Besançon, France), together with autol-
ogous irradiated PBMCs (5 × 104 cells/well), and Mycobacterium 
tuberculosis peptides ([MTPs] a pool of 6 synthetic peptides, 
2 µg/mL per peptide [Primm, Milan, Italy]) or Ca-Ag (25 µg/
mL [Bio-Rad, Hercules, CA]) for 18 hours at 37°C, in 5% CO2 
atmosphere. Biotinylated anti-IFNγ detection mAb (B-G1; 
Diaclone) was added (4 hours), followed by the streptavidin-al-
kaline phosphatase conjugate (1 hour) (Amersham Pharmacia 
Biotech Europe GmbH, Freiburg, Germany). After a wash-
ing step, the nitroblue tetrazolium-5-bromo-4-chloro-3-in-
dolylphosphate (Sigma) chromogenic substrate was added. 
Individual spot-forming cells were counted using an auto-
mated image analysis system ELISPOT reader (AID-GmbH, 
Strassberg, Germany). Mycobacterium tuberculosis peptides (20 
amino acids) were derived from the ESAT-6 and CFP-10 secre-
tory proteins of MTB, purified (>70%), and previously validated 
[31]. Peripheral blood mononuclear cells in medium alone or 
stimulated with phytohemagglutinin ([PHA-P] Sigma; 5 µg/mL) 
were used to assess assay background and functionality.
Flow Cytometry Analysis and Intracellular Cytokine Staining
Cells were harvested, washed with staining buffer (phos-
phate-buffered saline supplemented with 0.5% FCS and 
0.02% NaN3), and incubated with mAbs directed against 
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surface Ags for 15 minutes at room temperature. The follow-
ing fluorescence-conjugated mAbs were used: anti-CD3-v500, 
anti-CD8-allophyocyanine-H7, anti-CD27-phycoerythrine 
(PE), IL-2-fluorescein isothiocyanate, TNFα Alexa700 (all 
from BD Biosciences, Franklin Lakes, NJ); anti-CD4-peridi-
nin chlorophyll, anti-IFNγ PE-Cy7 (Cyanine-7), anti-CD154 
Pacific-Blue (BioLegend, Cambridge, UK); anti-CD45RA ECD 
(Beckman Coulter, UK); and Yellow live-dead stain (Thermo 
Fisher Scientific). Thereafter, cells were washed in staining 
buffer before acquisition.
Intracellular cytokine staining was used to measure MTP-
specific cytokine release at single-cell level. Equal numbers of 
CFSE-labeled cytokine-cultured cells (0.6 ×  106) were stimu-
lated (6 hours) with unpulsed (nil) or MTP-pulsed (4 µg/mL) 
autologous irradiated (5000 rad) PBMCs (3 × 106 cells), in the 
presence of human anti-CD28-stimulating mAb (2  µg/mL; 
BD Biosciences). In the last 5 hours of stimulation, Brefeldin 
A  (10  µg/mL; Sigma) was added. To measure CMV-/SEB-
specific cytokine release, equal numbers of cells were stimu-
lated with CMV lysate (2  µg/mL; Advanced Biotechnologies, 
Eldersburg, MD) or SEB (1  µg/mL) for 2 hours followed by 
14 hours in the presence of Brefeldin A. Thereafter, cells were 
washed, surface-stained as described above, fixed, permeabi-
lized, and stained with anti-CD4, anti-IL-2, anti-IFNγ, and/or 
anti-TNFα mAbs. Events were acquired on a BD FACSCalibur 
or LSRII, and data were analyzed using the FlowJo-v9.x soft-
ware (TreeStar Inc., Ashland, OR).
Statistical Analysis
GraphPad Prism 7.03 was used for statistical analyses. The 
D’Agostino-Pearson and Shapiro-Wilk tests were used to deter-
mine normality of data distribution. For normally distributed 
data that passed both tests, means and standard deviation are 
shown, and paired t tests are used to compare 2 groups. For 
non-normally distributed data, non-parametric paired tests 
(Wilcoxon test) were used to compare 2 groups. For multi-
ple-group comparisons, 2-way ANOVA with Sidak’s or Tukey’s 
multiple comparison corrections were used, as indicated in 
the figures. Levels of significance are as follows: *, P ≤ .05; **, 
P ≤ .005; and ***, P ≤ .0005, unless specified differently in indi-
vidual figures.
RESULTS
Interleukin-7 Enhances Recall Responses of Mycobaterium tuberculo-
sis-Specific CD4+ T Cells
To investigate putative effects of IL-7 on pathogen-specific T 
cells, we first analyzed chronically infected TB patients. These 
were chosen based on clinical history and manifestation of acute 
MTB infection (clinic and culture confirmed), positive reaction 
to the TST, and ability of PBMCs to respond to stimulation with 
major histocompatibility complex-II-restricted MTB-specific 
promiscuous peptides (MTPs) in IFNγ ELISPOT assays [31]. 
Patients with detectable (patient [Pt]#1 and Pt#2; Figure 1) or 
undetectable (Pt#3; Figure 1) MTB-specific IFNγ-producing T 
cells were analyzed. Cryopreserved cells were tested in MTP-
recall assays immediately after thawing (day [d]0; Figure  1A 
and B) or at the end of a culture (d7) in IL-7 compared with 
complete media (med). Not all patients with detectable MTP-
specific T-cell responses on fresh PBMCs [31] had a detect-
able MTP response after thawing, as seen in the case of Pt#2, 
compared with Pt#1. Nonetheless, we found that IL-7 selec-
tively enriched cultures for MTP-specific IFNγ+ T cells by 4- to 
10-fold in all cases (Figure 1B). Although MTP-specific T cells 
could also expand in control cultures (as seen for Pt#1, med), 
this was best explained by the increase of total CD3+CD4+ T 
cells in some patients (data not shown). It is important to note 
that the frequency of MTP-specific cells increased in IL-7 cul-
tures more than the levels found in control cultures, even if the 
percentage of total CD3+CD4+ T cells remained similar. Of note, 
IL-7 also allowed us to detect MTP-specific T cells in samples 
derived from immunosuppressed patients (ie, anergic; Pt#3). 
Sensitization with IL-7 significantly increased absolute numbers 
of MTP-specific T cells in all the TB patients analyzed (n = 5; 
Figure  1C) compared with non-Bacillus Calmette-Guérin-
vaccinated healthy donors (non-MTB-infected controls, n = 8).
To independently confirm the presence of MTP-specific T 
cells, we additionally performed ICS after MTP stimulation. 
Mycobacterium tuberculosis peptide-pulsed irradiated autol-
ogous PBMCs were used as Ag-presenting cells (APCs). As 
with ELISPOT assays, in ICS we found that the frequency 
of MTP-specific, IL-2+IFNγ+ CD4 T cells increased in IL-7 
cultures, compared with freshly thawed PMBCs (d0) and 
control cultures (med; Supplementary Figure  1). Thus, 
MTB-specific T-cell recall responses are enhanced after sen-
sitization with IL-7.
Interleukin-7 Supports Fungal and Viral-Specific CD4 T-Cell Accumulation 
in Peripheral Blood Mononuclear Cells From Infected Individuals
We then asked whether exposure to IL-7 would also drive the 
accumulation of CD4 T cells specific for fungal Ags derived 
from endemic pathogens, such as Ca. Freshly thawed PBMCs 
derived from individuals with recurrent Ca infections were 
immediately analyzed for IFNγ expression in Ca-Ag-recall 
ELISPOT, in the presence of Ag-pulsed irradiated autologous 
PBMCs as APCs (d0; Figure 2), or seeded in culture with or 
without IL-7 (d7 and med, respectively; Figure 2), and analyzed 
after 7 days. As in the case of TB-specific T cells, Ca-Ag-specific 
IFNγ spots were also remarkably increased in IL-7-driven cul-
tures, compared with controls (d0 and med; Figure  2A). In 
multiple individuals (n = 4), Ca-Ag-specific effectors were sig-
nificantly increased by ~10-fold over the levels found at d0 after 
IL-7 exposure compared with control medium (Figure 2B).
Because CMV-specific CD4 T cells have been recently shown 
to significantly expand in elderly individuals chronically infected 
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Figure 2. Interleukin (IL)-7 supports the expansion and effector function of Candida albicans (Ca)-specific T cells. (A) After thawing, peripheral blood mononuclear cells 
from a donor with recurrent Ca infection were analyzed for the release of the effector cytokine, interferon (IFN)γ, using a Ca-antigen (Ag)-specific enzyme-linked immunospot 
assay at the time of thawing (day [d]0) and after a 7-day culture in the absence (d7, control medium [med]) or presence of human recombinant IL-7 (d7, IL-7). Background IFNγ 
release was measured in Ag-unpulsed control wells (nil, top wells) in the presence of irradiated autologous feeder cells. (B) The range and average fold increase of Ca-Ag-
specific IFNγ spots in control medium (med vs d0, white bar) and IL-7 (IL-7 vs d0, dotted bar) cultures over the levels found after thawing (d0) is shown. Statistically significant 
accumulation of Ca-Ag-specific IFNγ-spots was evaluated in multiple donors (n = 4) using a paired t test. *P ≤ .05; **, P ≤ .005; ***, P ≤ .0005.
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Figure 1. Interleukin (IL)-7 enhances Mycobacterium tuberculosis (MTB)-specific T-cell responses. (A) Cryopreserved peripheral blood mononuclear cells (PBMCs) from 
tuberculosis (TB) patients were analyzed for interferon (IFN)γ release by MTB-specific peptide (MTP) enzyme-linked immunospot (ELISPOT) assay at the time of thawing (day 
[d]0) and after a 7-day culture in the absence (control medium [med], dashed line) or presence of human recombinant IL-7 (solid line), in parallel to unstimulated controls 
(nil). For each patient, 2 duplicate vials were sequentially thawed, staggered in time (dash dotted lines): the first vial was used to set up the cultures at d0 (left dashdotted 
arrow); the second vial was thawed 7 days later (right dash dotted arrow) to provide for the following: (1) ex vivo control cells to be analyzed in parallel to cultured cells and 
(2) autologous feeder cells for the restimulation assays (refer to Materials and Methods for details). (B) Background IFNγ release was measured for any condition in antigen 
(Ag)-unpulsed control wells (nil), as representatively depicted for patient (Pt.)#1 (top row). The IFNγ-spots after restimulation with MTP promiscuous peptides were detected 
in 3 TB patients (Pt. #1, #2, and #3) after thawing (d0) and/or a 7-day culture (d7) in IL-7 or med. (C) The effect of the IL-7 treatment (d0 vs d7, IL-7) on MTP-specific IFNγ-spot 
accumulation in PBMCs derived from healthy donors (open circles, n = 8) and MTB-infected patients (open triangles, n = 5) was analyzed by the ELISPOT assay in multiple 
individuals. Statistical significance was determined using a 2-way analysis of variance with Sidak’s multiple comparison correction to evaluate (1) the effect of IL-7 treatment 
in the 2 different groups over time and (2) the diagnostic power of the discrimination of the 2 groups before and after IL-7 treatment, as indicated: *, P ≤ .05; **, P ≤ .005.
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with the endemic CMV [32, 33], we investigated CMV-specific 
CD4 T-cell responsiveness to IL-7 in cultures derived from 
CMV-seropositive (CMV+) patients. CMV-seronegative (CMV−) 
individuals were used as controls. Freshly derived PBMCs were 
cultured in the presence of IL-7 or control medium (med) for 
7 days, and then CMV-recall responses were tested in ICS, using 
total CMV lysate as a source of viral Ags (Figure 3A, top). Again, 
cells cultured in IL-7 tended to show higher CMV-recall responses 
compared with controls (Figure 3A). Of note, these CMV-specific 
T cells were mostly polyfunctional, TNFα+IFNγ+-producing cells 
(Figure 3A) and remained undetectable in cultures derived from 
CMV− individuals (Supplementary Figure 2A). Because we found 
that T cells express varying amounts of CD127 and upregulate it 
in control medium (Supplementary Figure 2B), as expected [34], 
we first rested freshly thawed PBMCs for 5 days, and then we sub-
jected them to IL-7-driven cultures (Figure 3B, top). Under these 
conditions, we found that IL-7 more potently and reproducibly 
enabled the accumulation of CMV-specific T-cell responses from 
CMV+ individuals (n = 10; Figure 3C). The IFNγ+ cells expressed 
low levels of CD127, indicative of IL-7-driven receptor down-
modulation [34], upon cytokine-driven activation (Figure  3D) 
while maintaining high levels of LFA-1 (data not shown) and 
polyfunctional cytokine expression (Figure 3B). Thus, in addition 
to bacterial responses, fungal and viral-specific responses are also 
enhanced by IL-7 signals.
Interleukin-7 Promotes Responsiveness of Staphylococcus 
 aureus- Specific T Cells
Bacterial superantigens, such as SEB, can lead to T-cell anergy 
[35] or suppression [36]. We asked whether culturing the cells 
in IL-7 might also help SEB-specific T-cell responses (Figure 4). 
The PBMCs from healthy donors were rested 5 days in control 
medium and then left untreated or cultured in IL-7 for 7 days. 
The SEB-recall responses were then tested in ICS (Figure 4A, 
top). We found that although SEB-specific T cells could be 
detected in control PBMC cultures (med), IFNγ+ or TNFα+ and 
TNFα+IFNγ+ cells were all enriched for in IL-7-driven cultures 
from many individuals, significantly (Figure 4A and B, n = 17). 
As seen for CMV-specific T cells (Figure 3D), cytokine+ SEB-
specific cells expressed lower levels of CD127 (Figure 4C) while 
maintaining high levels of LFA-1 (data not shown).
We also tested whether IL-7 is capable of supporting SEB-
responsiveness even after Ag-driven expansion, in vitro 
(Figure  4D). We found that IL-7 significantly enhanced 
responses after SEB-restimulation (Figure 4D). Thus, cultur-
ing T cells in IL-7 either before or after Ag recall allows for a 
higher frequency of Ag-specific cells to be identified.
Interleukin-7 Drives Cyclosporine A-Sensitive Central Memory T-Cell 
Division
In a previous mouse study, we found that IL-7 favored the in 
vitro expansion of tumor-Ag-experienced T cells, by promoting 
their proliferation [29]. Thus, we asked whether IL-7-driven 
accumulation of human, pathogen-specific T cells also requires 
cell division. To this aim, we set up CFSE-labeled PBMC cul-
tures (Figure 5A and B). We found that although a small frac-
tion of CD4 T cells derived from healthy donors (~1%–10%) 
underwent several rounds of “spontaneous” (ie, in the absence 
of any introduced stimulation) cell division in complete 
media (Figure 5A, top panel), dividing cells were dramatically 
increased upon IL-7 addition (Figure 5A, bottom panel). These 
cells expressed high levels of Bcl-2 (Supplementary Figure 3), in 
agreement with the prosurvival role of the cytokine [20]. More 
importantly, IL-7 favored the expansion of 2 cell populations, 
distinguishable for their proliferation potential (ie, either fast 
or slow; F and S, respectively, in the figures) and with distinct 
mechanistic requirements. Indeed, although both populations 
were best detected in high-density cell cultures (Supplementary 
Figure  4), they proved differentially sensitive to CSA. Fast- 
but not slow-dividing cells were sensitive to CSA inhibition 
(Figure  5B). In addition, fast-dividing cells were sensitive to 
anti-LFA-1 mAb blockade (Supplementary Figure 5), suggesting 
that cell-to-cell contacts are also required for their proliferation. 
Of note, IL-7 elicited similar effects in autologous sera and FCS 
(Supplementary Figure 4). We reckoned that, although slow-di-
viding cells represent cells undergoing homeostatic expan-
sion, known to occur via CSA-insensitive mechanisms [19] 
(Figure  5B, right panel in top row), fast-dividing cells may 
represent a distinct population of Ag-experienced memory 
cells proliferating via a CSA-sensitive mechanism (Figure  5B, 
middle-right panel in top row). Flow cytometry analysis indi-
cated that although both TCM (CD45RA−, CD62L+) and TEM 
(CD45RA−, CD62L−) cells accumulated in response to IL-7 
(Figure 5B, middle and bottom panel), only fast-dividing TCM 
(CD45RA−, CD62L+) cells appeared sensitive to CSA (Figure 5B, 
bottom panel). It is interesting to note that the IL-7-driven 
accumulation of CMV (Figure 5C, top), SEB (n = 15; Figure 5C, 
bottom and right), and MTB-specific (Supplementary Figure 6) 
polyfunctional memory T cells was also completely dependent 
upon CSA-sensitive signaling. Taken together, our data indicate 
that IL-7-driven cultures might recapitulate the events account-
ing for the maintenance of Ag-experienced memory T-cell sub-
sets in vivo [15] and improve their identification and selection 
in vitro.
DISCUSSION
In this study, we demonstrate that IL-7 supports the in vitro 
expansion of human pathogen-specific T cells, favoring and, 
in some instances, enabling their enumeration and charac-
terization. Interleukin-7-sensitive pathogen-specific effectors 
included cells specific for endemically diffused pathogens (eg, 
S aureus, C albicans, CMV, and MTB, in parts of the world), 
infecting humans recurrently during the lifetime, persisting 
(MTB) and/or reactivating in the body (CMV). Thus, our data 
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Figure 3. Interleukin (IL)-7 supports the accumulation of antiviral cytomegalovirus (CMV)-specific T cells. (A) Freshly derived peripheral blood mononuclear cells (PBMCs) 
from CMV+ donors were analyzed for inflammatory cytokine release after CMV-lysate intracellular cytokine staining (ICS) assay after a 7-day culture in the absence (d7, con-
trol medium [med], dashed black line) or presence of human recombinant IL-7 (d7, IL-7, black line). Left and right dot plots show the levels of IL-2 and tumor necrosis factor 
(TNF)α or interferon (IFN)γ and TNFα in gated CD4 T cells, respectively. Background levels of cytokine secretion were typically measured in unstimulated controls (nil). (B) 
Freshly isolated PBMCs from CMV+ donors were rested for 5 days in plain medium (dashed black line) before a 7-day culture in the absence (d12, med, dashed black line) or 
presence of human recombinant IL-7 (d12, IL-7, black line). At day 12 (d12), CD4+ T cells were analyzed for IFNγ and TNFα release (top row) alongside expression of CD127 
(bottom row), after CMV-lysate ICS assay. Cytomegalovirus-specific IFNγ+ CD4+ T cells show high CD127 expression in the resting cultures, whereas they downregulated 
CD127 expression upon exposure to IL-7. Background levels of cytokine secretion were typically measured in ICS unstimulated (nil) controls. A representative of >10 inde-
pendent experiments is shown. (C) After subtraction of individual background levels of IFNγ+ and TNFα+ and IFNγ+TNFα+ CD4 T cells detected in unstimulated controls (nil), 
the percentage of CMV-specific cytokine+ (IFNγ+ and TNFα+) CD4 T cells was evaluated in 10 independent CMV+ donors in IL-7 (IL-7, open triangles) compared with control 
medium ([med], open circles) cultures. The graph shows a statistically significant (paired Wilcoxon test, *P = .03) increase of the frequency (Log10) of CMV-specific CD4 T 
cells after IL-7 culture. (D) CD127 expression (Log10 mean fluorescence intensity [MFI]) is significantly downregulated in CMV-specific IFNγ
+CD4+ T cells exposed to IL-7 (IL-7) 
compared with control medium (med) at d12 in 6 biologically independent replicates (paired Wilcoxon test, *P = .03).
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Figure 4. Interleukin (IL)-7 supports superantigen-specific responses. (A) Freshly isolated peripheral blood mononuclear cells (PBMCs) were rested for 5 days in plain 
medium (dashed black line) then incubated for 1 week in IL-7 or control medium ([med] respectively IL-7, black line and med, dashed black line). At day (d)12, cells were 
stimulated with Staphylococcus aureus enterotoxin B (SEB) followed by an intracellular cytokine staining (ICS) assay to test antigen (Ag)-specific tumor necrosis factor (TNF)α 
and interferon (IFN)γ release, compared with unstimulated controls (nil). Dot plots show that the frequency of SEB-specific CD4+ T cells producing TNFα and/or IFNγ increased 
upon exposure to IL-7 in 1 representative donor. (B) After subtraction of individual background levels of IFNγ+ and TNFα+ and IFNγ+TNFα+ CD4 T cells detected in unstimulated 
controls (nil), the percentage of SEB-specific cytokine+ (IFNγ+, TNFα+, IFNγ+TNFα+ and total) CD4 T cells was evaluated in 17 independent donors in IL-7 (IL-7, open triangles) 
compared with control medium (med, open circles) cultures. The graphs show a statistically significant increase of the frequency (Log10) of SEB-specific cytokine
+ CD4 T cells 
after IL-7 culture. All tests are paired Wilcoxon tests with the exception of the single TNFα+ analysis (paired t test): *, P ≤ .05; **, P ≤ .005; ***, P ≤ .0005. (C) At d12, cells 
cultured as in (A) were tested for CD127 expression in parallel to cytokine release in SEB-specific ICS assay. CD127 expression (Log10 mean fluorescence intensity [MFI]) is 
significantly decreased in SEB-specific IFNγ+ CD4+ T cells exposed to IL-7 (IL-7, downward triangles) compared with control medium (med, upward triangles) in 12 independent 
biological replicates (paired Wilcoxon test; ***, P = .0005). (D) Freshly isolated PBMCs (d0) were stimulated with the SEB superantigen (dotted black line) for 5 days (d0–5). 
At d5, cells were washed and incubated for 1 week in IL-7 (IL-7, black line; d5–12) or control medium (med, dashed black line; d5–12). At d12, cells were stimulated with SEB 
(overnight) to test Ag-specific TNFα and IFNγ release, by ICS. Dot plots show that the frequency of SEB-specific CD4+ T cells producing TNFα and/or IFNγ increased upon 
exposure to IL-7 (IL-7 d5–12, top row). The graph on the right shows data from the same cultures derived from 6 independent biological replicates. Statistically significant 
accumulation of SEB-specific, cytokine+ CD4+ T cells was evaluated using a Wilcoxon matched-pairs signed-ranked test (P = .03).
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Figure 5. Sensitization by interleukin (IL)-7 promotes pathogen-specific CD4+ T cell proliferation in a cyclosporine A (CSA)-sensitive manner. 5-(and-6)-carboxyfluorescein 
diacetate succinimilyl ester (CFSE)-labeled peripheral blood mononuclear cells (PBMCs) (A–C) from healthy donors (A and B) were cultured for 7 days in the absence (med) or 
presence of human recombinant IL-7 (IL-7). (A) Proliferation of viable CD4 T cells in high-density cultures (5 × 106 cells/mL) was determined by flow cytometry after staining 
with anti-CD4 monoclonal antibody (mAb) and TO-PRO-3 (an intercalant agent of deoxyribonucleic acid entering necrotic and apoptotic cells). Contour plots depict the rela-
tive CFSE content within the same number of viable, TO-PRO-3− CD4+ T cells. (B) Cells cultured (4 × 106 cells/mL) in the presence of IL-7 for 7 days in the absence or in the 
presence of CSA. At d7, cells were stained with anti-CD4, anti-CD45RA, and anti-CD62L mAb, and the relative CFSE content was analyzed by flow cytometry in total CD4 T 
cells (top row). Fast- (F), slow- (S), and nondividing cells were determined based on CSA inhibition, as indicated. The percentage of naive (CD45RA+CD62Lhi), central memory 
(CD45RA−CD62Lhi), and effector memory (CD45RA−CD62Llo) cells were then investigated in slow- compared with fast-proliferating CD4 T cells. (C) Freshly isolated PBMCs 
were rested for 5 days then incubated for 1 week in IL-7 or IL-7 plus CSA (IL-7+CSA). At d12, cells were stimulated with Staphylococcus aureus enterotoxin B (SEB) during an 
intracellular cytokine staining (ICS) assay to test antigen-specific tumor necrosis factor (TNF)α and interferon (IFN)-γ release, compared with unstimulated controls (refer to 
Figures 3 and 4). Left dot plots show that the IL-7-driven accumulation of (top) cytomegalovirus (CMV)- and (bottom) SEB-specific CD4+ T cells producing TNFα and/or IFNγ 
is reversed in the presence of CSA, by d12. After subtraction of individual background levels of IFNγ+, TNFα+, and IFNγ+TNFα+ CD4 T cells detected in unstimulated controls 
(nil), the percentage of SEB-specific cytokine+ (IFNγ+, TNFα+, IFNγ+TNFα+, and total) CD4 T cells was evaluated in 15 independent biological replicates in IL-7 (open circles) 
compared with IL-7+CSA cultures (open triangles). The right graphs show a statistically significant decrease in the frequency (Log10) of SEB-specific cytokine
+ (except for 
IFNγ+) CD4 T cells in the presence of CSA at d12. All tests are paired Wilcoxon tests; *, P ≤ .05; **, P ≤ .005; ***, P ≤ .0005.
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will help the study and isolation of such pathogen-specific T 
cells and others relevant to various clinical settings, includ-
ing harmful infections, especially in the case of immune-sup-
pressed (HIV, transplantation, aged etc) or chronically infected 
individuals, in which pathogen-specific T cells might be low in 
frequency and/or hyporesponsive.
Previous studies showed that IL-7 can support immune-
cell reconstitution in lymphopenic conditions [22–25], restore 
sepsis-induced lymphocyte dysfunctions ([37, 38]), enhance 
effector function of autoreactive T cells [8–13], and expand 
tumor-reactive T cells [29, 30]. We then asked whether patho-
gen-reactive T cells also benefited from IL-7 exposure. Our 
results show that IL-7 promotes the selective expansion of a 
fraction of memory CD4+ T cells containing pathogen-specific 
cells, best observed in high cell-density cultures. Although IL-7 
significantly enhanced overall cell recovery (by ~1.5-fold), cyto-
kine-producing CD4 T cells were not enriched at a polyclonal 
level (as detected by 12-O-tetradecanoyl-phorbol-13-acetate 
and ionomycin stimulation; Supplementary Figure  7) unlike 
that seen for pathogen-specific cells. These cells showed a fast 
rate of proliferation, sensitive to CSA and LFA-1 inhibition, 
both in autologous sera and FCS. Thus, neither homeostatic cell 
division [19, 39–42], known to be CSA insensitive [19, 42], nor 
food-related, bovine Ags seem to account for the accumulation 
of fast-dividing cells. However, our results suggest the existence 
of a cell-associated ligand capable of synergizing with IL-7 sig-
nals to promote the proliferation and responsiveness of patho-
gen-specific T cells. We speculate that self-Ag/TCR-initiated 
signals may play a role in the IL-7 cultures.
Although further research is needed to identify such sig-
nals in IL-7 cultures, our data support a role for IL-7 in T cell-
driven immunopathology in chronic and persistent infections, 
coinfections, or autoimmunity. Accordingly, IL-7 is expressed 
in inflamed tissues of patients with (rheumatic) autoimmune 
diseases, where it can be produced by several cell types [43] 
(including macrophages, dendritic cells, and fibroblasts) and 
favor pathogenic Th1- and Th17-associated cytokine secre-
tion. Furthermore, dysregulated IL-7 expression or activation 
of CD127 were found in patients with autoimmune conditions 
[8–13], suggesting that IL-7 supports the function of patho-
genic effector cells in autoimmunity. In agreement  with this, 
blocking the IL-7R in experimental animal models amelio-
rated autoimmune disease manifestations [44]. Thus, together 
with available data, our results suggest that IL-7 might awaken 
auto-reactive T cells, or pathogen-specific effector T cells with 
cross-reactivity to self-Ag, hence contributing to autoimmu-
nity. However, this might not equally apply to patients with 
immune dysfunctions due to sepsis or chronic HIV/hepatitis 
C virus infection. Indeed, IL-7 administration mainly in HIV-
infected or immunosuppressed patients was generally well tol-
erated [22, 23, 25, 27, 28, 45], with a single report of a patient 
developing systemic lupus erythematosus after 3 doses of IL-7 
[45]. We speculate that the risk of developing autoimmunity 
after IL-7 treatment may vary dependent on individual clin-
ical history, genetic predisposition, and the administration 
regimen. Further studies are needed to define the long-term 
consequences of IL-7 administration.
It is interesting to note that among memory cells, poly-
functional T cells (double positive for IFNγ+ and IL-2+ or 
TNFα+) were mostly enriched for by IL-7. Such cells were 
detected in subjects with chronic viral (including CMV [32]) 
infections and previously referred to as intermediate poly-
functional memory cells [46]. It is possible that IL-7 favors 
differentiation of these cells in vitro (and possibly also in 
vivo), starting from IFNγ-producing cells. With respect to 
maintaining polyfunctional T cells, IL-7 appears superior 
to the cognate Ag by favoring (central) memory cell sur-
vival [15–17], rather than terminal differentiation, acti-
vation-induced cell death, and/or exhaustion [29]. Thus, 
IL-7 may be useful for the expansion of human polyclonal 
and polyfunctional pathogen-specific CD4 (and to a lower 
extent, CD3+CD4− or CD8+; Supplementary Figure  8A–E) 
T cells that are hard to identify, even in the case of a rel-
atively well studied pathogen (such as CMV [47, 48]). 
Accordingly, exposing cells to IL-7 enabled better enumer-
ation of in vivo-primed CMV-/SEB-specific cells, although 
these trends were less apparent in CD8+ T cells, which did 
not undergo fast proliferation to the extent of CD4 T cells 
(Supplementary Figure  8F). This was also the case when T 
cells were Ag-restimulated in vitro before the IL-7 culture, 
opening the possibility that IL-7 (with or without Ag) might 
be superior to Ag alone in expanding T cells derived from in 
vivo-primed individuals. Our data also support the hypoth-
esis that IL-7 sustains the preferential accumulation of poly-
functional T-cell subsets within the repertoire of certain 
individuals, including perhaps the inflated responses of CD4 
T cells detected in elderly CMV+ individuals [32, 33]. Future 
studies are needed to address this possibility.
CONCLUSIONS
We previously suggested that among other CD132-cytokines, 
IL-7 played nonredundant roles and outperformed IL-2 in 
driving Ag-experienced T-cell accumulation and mediating 
the expansion of less differentiated cells useful for gene therapy 
[26, 30]. We now provide evidence supporting the use of IL-7 to 
reveal and expand in vivo-primed pathogen-specific lympho-
cytes of clinical relevance, either as biomarkers of viral infection 
and disease activity [49] or as therapeutic tools. This may be rel-
evant for the treatment of chronic infectious diseases and can-
cer, because adoptive immunotherapy with less differentiated T 
cells is preferable over the transfer of terminally differentiated 
effectors [50].
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